For decades, blood pressure instability has silently debilitated people with spinal cord injuries—78% of those with cervical injuries experience dangerous drops when sitting upright, yet only 28% receive treatment that actually works. ONWARD Medical just enrolled the first participant in a pivotal trial testing whether an implanted spinal cord stimulator can solve this problem by restoring the autonomic signals that paralysis disrupts.
For decades, blood pressure instability has silently debilitated people with spinal cord injuries—78% of those with cervical injuries experience dangerous drops when sitting upright, yet only 28% receive treatment that actually works. ONWARD Medical just enrolled the first participant in a pivotal trial testing whether an implanted spinal cord stimulator can solve this problem by restoring the autonomic signals that paralysis disrupts.
The Empower BP trial represents a new frontier for spinal cord stimulation technology. While epidural stimulators have already enabled paralyzed individuals to walk again in research settings, this study targets a less visible but equally life-limiting consequence of spinal cord injury: the inability to maintain stable blood pressure during everyday activities like sitting, eating, or physical therapy.
First Patient Enrolled in Empower BP Pivotal Trial
Clinical Trial
ONWARD Medical enrolled the first participant at Craig Hospital in the randomized, double-blinded Empower BP study testing the implantable ARC-IM system for blood pressure instability after spinal cord injury.
FDA Clears ARC-EX for Home Use
Regulatory
The FDA granted 510(k) clearance expanding the ARC-EX system indication to allow patients to use the non-invasive stimulator at home.
Blood Pressure Feasibility Results Published
Research
Nature Medicine published multi-year feasibility data showing the ARC-IM implant produced immediate blood pressure increases, reduced symptoms, and improved quality of life lasting up to two years.
First Commercial Sales of ARC-EX
Commercial
ONWARD Medical announced first commercial sales of the ARC-EX system in the United States, days after FDA approval.
FDA Approves First Non-Invasive Spinal Cord Stimulator
Regulatory
The FDA granted De Novo classification to ONWARD's ARC-EX system, making it the first FDA-approved technology shown to improve hand strength and sensation after chronic spinal cord injury.
Ottobock Invests €50M, Takes 10% Stake
Corporate
ONWARD Medical raised €50 million including a cornerstone investment from prosthetics leader Ottobock, establishing a strategic partnership for commercialization.
UP-LIFT Trial Results Published
Clinical Trial
Nature Medicine published results from the 65-participant UP-LIFT trial showing 90% of participants improved upper limb strength or function with non-invasive ARC-EX stimulation.
Brain-Spine Interface Enables Natural Walking
Research Breakthrough
Researchers published in Nature a brain-computer interface linked to spinal stimulation that enabled a man with chronic tetraplegia to walk naturally in community settings, with stability maintained for over one year.
Same-Day Recovery Demonstrated in Complete Paralysis
Research Breakthrough
Three individuals with complete sensorimotor paralysis stood, walked, cycled, and swam within a single day of implant activation, published in Nature Medicine.
ONWARD Medical Goes Public on Euronext
Corporate
The company completed its initial public offering on the Euronext stock exchange, raising capital to advance clinical development.
FDA Grants First Breakthrough Designation for Movement Restoration
Regulatory
ONWARD Medical received its first FDA Breakthrough Device Designation for the ARC-IM system to restore leg motor function in people with spinal cord injury.
Paraplegic Patients Walk with Targeted Stimulation
Research Breakthrough
EPFL and Lausanne University Hospital researchers demonstrated that activity-specific epidural stimulation programs enabled three paralyzed patients to walk, including outdoors, after five months of rehabilitation.
Four Paralyzed Men Move Legs Voluntarily
Research Breakthrough
Expanded study published in Brain showed epidural stimulation enabled four men with complete paralysis to voluntarily control their legs, challenging the belief that complete paralysis is permanent.
ONWARD Medical Founded
Corporate
Grégoire Courtine and Jocelyne Bloch founded GTX Medical (later renamed ONWARD Medical) to commercialize their spinal cord stimulation research from EPFL.
First Paralyzed Patient Regains Movement with Epidural Stimulation
Research Breakthrough
Rob Summers, paralyzed after being struck by a vehicle, became the first person to regain voluntary movement through epidural electrical stimulation in a study published in The Lancet by University of Louisville, UCLA, and Pavlov Institute researchers.
Scenarios
1
FDA Approves Implant for Blood Pressure, Opens New Market
Discussed by: Industry analysts covering ONWARD Medical; medical device market reports
If Empower BP meets its primary endpoints, the FDA could approve the ARC-IM system for blood pressure instability by 2028-2029. This would create a new treatment category for approximately 350,000 people in the US and Europe who experience this complication. Given ONWARD's track record with breakthrough designations and the ARC-EX approval, the regulatory pathway appears established. Success would validate the company's strategy of expanding from movement restoration to autonomic function recovery.
2
ARC-IM Becomes Multi-Indication Platform
Discussed by: ONWARD Medical investor communications; neurotechnology researchers
With 10 FDA Breakthrough Device Designations covering movement, blood pressure, trunk stability, bladder control, and spasticity, ONWARD could pursue additional pivotal trials for the ARC-IM implant. A single surgical implant addressing multiple complications would substantially increase the value proposition for patients and healthcare systems. The company's partnership with Ottobock and recent brain-computer interface licensing suggest this platform strategy is underway.
3
Trial Fails, Setback for Autonomic Therapies
Discussed by: Clinical trial analysts; medical device investors
Pivotal trials are inherently uncertain. If Empower BP fails to meet its primary endpoints—demonstrating statistically significant improvement in orthostatic hypotension management compared to sham stimulation—it would delay autonomic function treatments for spinal cord injury patients and potentially impact ONWARD's stock and ability to fund additional indications. However, the strong feasibility data showing two-year benefit durability reduces this risk.
4
Major Medical Device Company Acquires ONWARD
Discussed by: Medical device industry analysts; investment banking reports
ONWARD's proven regulatory pathway, multiple breakthrough designations, and first-mover advantage in spinal cord stimulation for paralysis make it an acquisition target for larger neuromodulation companies like Medtronic, Abbott, or Boston Scientific. The €50 million Ottobock investment at a 10% stake implies a valuation that could attract strategic interest, particularly if the Empower BP trial succeeds.
Historical Context
Deep Brain Stimulation for Parkinson's Disease (1987-1997)
1987-1997
What Happened
French neurosurgeon Alim-Louis Benabid discovered that high-frequency electrical stimulation of the thalamus could suppress tremors in Parkinson's patients. Medtronic commercialized the therapy, which received FDA approval in 1997 for essential tremor and 2002 for Parkinson's disease.
Outcome
Short Term
Deep brain stimulation offered an alternative to brain lesioning surgery, with adjustable and reversible effects.
Long Term
DBS became standard of care for advanced Parkinson's, with over 200,000 patients treated. It established the business model and regulatory pathway for implantable neurostimulation therapies.
Why It's Relevant Today
ONWARD's spinal cord stimulators follow the same translation pattern: academic discovery, breakthrough device designation, pivotal trials, FDA approval, and commercialization by a specialized company. The DBS precedent shows how neurostimulation can evolve from experimental to standard of care over 10-15 years.
Cochlear Implants Restore Hearing (1984-Present)
1984-present
What Happened
The FDA approved the first cochlear implant in 1984, enabling deaf individuals to perceive sound through direct electrical stimulation of the auditory nerve. Early devices provided limited benefit, but decades of refinement dramatically improved outcomes.
Outcome
Short Term
Initial cochlear implants helped only profoundly deaf adults; children were not candidates until 1990.
Long Term
Over one million people worldwide now use cochlear implants. Most deaf children in developed countries receive implants, and many achieve near-normal language development. The technology created a multi-billion dollar industry.
Why It's Relevant Today
Like cochlear implants, spinal cord stimulation for paralysis replaces lost neural function with electrical signals. The cochlear implant trajectory—from crude early devices to sophisticated systems that restore near-normal function—suggests what may be possible as spinal cord stimulation technology matures over the next two decades.
Spinal Cord Stimulation for Chronic Pain (1967-Present)
1967-present
What Happened
Norman Shealy implanted the first spinal cord stimulator for chronic pain in 1967, based on the gate control theory that electrical stimulation could block pain signals. Medtronic, Boston Scientific, and Abbott developed commercial systems that now represent a multi-billion dollar market.
Outcome
Short Term
Early spinal cord stimulators were crude and had high complication rates, limiting adoption.
Long Term
The global spinal cord stimulation market reached approximately $2.5 billion annually, with devices implanted in hundreds of thousands of patients for failed back surgery syndrome and other chronic pain conditions.
Why It's Relevant Today
ONWARD's technology repurposes the same basic approach—epidural electrical stimulation—for a fundamentally different goal: restoring function rather than blocking pain. The established supply chains, surgical expertise, and reimbursement frameworks for pain stimulators provide infrastructure that could accelerate adoption of function-restoring stimulators.
